• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

产碳青霉烯酶肺炎克雷伯菌血流感染患者的死亡预测因素及恰当抗菌治疗的影响。

Predictors of mortality in patients with bloodstream infections caused by KPC-producing Klebsiella pneumoniae and impact of appropriate antimicrobial treatment.

机构信息

Department of Microbiology, Tzaneio General Hospital, Piraeus, Greece.

出版信息

Clin Microbiol Infect. 2011 Dec;17(12):1798-803. doi: 10.1111/j.1469-0691.2011.03514.x. Epub 2011 May 20.

DOI:10.1111/j.1469-0691.2011.03514.x
PMID:21595793
Abstract

Bloodstream infections (BSIs) caused by Klebsiella pneumoniae carbapenemases (KPC)-producing K. pneumoniae (KPC-KP) are associated with high mortality rates. We investigated outcomes, risk factors for mortality and impact of appropriate antimicrobial treatment in patients with BSIs caused by molecularly confirmed KPC-KP. All consecutive patients with KPC-KP BSIs between May 2008 and May 2010 were included in the study and followed-up until their discharge or death. Potential risk factors for infection mortality were examined by a case-control study. Case-patients were those who died from the BSI and control-patients those who survived. Appropriate antimicrobial therapy was defined as treatment with in vitro active antimicrobials for at least 48 h. A total of 53 patients were identified. Overall mortality was 52.8% and infection mortality was 34%. Appropriate antimicrobial therapy was administered to 35 patients; mortality due to infection occurred in 20%. All 20 patients that received combination schemes had favourable infection outcome; in contrast, seven of 15 patients given appropriate monotherapy died (p 0.001). In univariate analysis, risk factors for mortality were age (p <0.001), APACHE II score at admission and infection onset (p <0.001) and severe sepsis (p <0.001), while appropriate antimicrobial treatment (p 0.003), combinations of active antimicrobials (p 0.001), catheter-related bacteraemia (p 0.04), prior surgery (p 0.014) and other therapeutic interventions (p 0.015) were significantly associated with survival. Independent predictors of mortality were age, APACHE II score at infection onset and inappropriate antimicrobial treatment. Among them, appropriate treatment is the only modifiable independent predictor of infection outcome.

摘要

血流感染(BSI)由产碳青霉烯酶肺炎克雷伯菌(KPC)的肺炎克雷伯菌(KPC-KP)引起,与高死亡率相关。我们研究了分子确诊为 KPC-KP 引起的 BSI 患者的结局、死亡风险因素和适当抗菌治疗的影响。研究纳入了 2008 年 5 月至 2010 年 5 月期间所有连续的 KPC-KP BSI 患者,并进行随访,直至患者出院或死亡。通过病例对照研究检查了感染死亡的潜在风险因素。病例患者是因 BSI 死亡的患者,对照患者是存活的患者。适当的抗菌治疗定义为至少 48 小时的体外活性抗菌药物治疗。共确定了 53 例患者。总死亡率为 52.8%,感染死亡率为 34%。35 例患者接受了适当的抗菌治疗;感染死亡 20%。接受联合方案的 20 例患者均获得良好的感染结局;相比之下,15 例接受适当单一疗法的患者中有 7 例死亡(p<0.001)。单因素分析显示,死亡的风险因素是年龄(p<0.001)、入院时和感染发病时的急性生理学和慢性健康状况评分 II(APACHE II)评分(p<0.001)以及严重脓毒症(p<0.001),而适当的抗菌治疗(p=0.003)、活性抗菌药物的联合应用(p=0.001)、导管相关菌血症(p=0.04)、既往手术(p=0.014)和其他治疗干预(p=0.015)与生存显著相关。死亡的独立预测因素是年龄、感染发病时的 APACHE II 评分和不适当的抗菌治疗。其中,适当的治疗是感染结局的唯一可改变的独立预测因素。

相似文献

1
Predictors of mortality in patients with bloodstream infections caused by KPC-producing Klebsiella pneumoniae and impact of appropriate antimicrobial treatment.产碳青霉烯酶肺炎克雷伯菌血流感染患者的死亡预测因素及恰当抗菌治疗的影响。
Clin Microbiol Infect. 2011 Dec;17(12):1798-803. doi: 10.1111/j.1469-0691.2011.03514.x. Epub 2011 May 20.
2
Predictors of mortality in bloodstream infections caused by Klebsiella pneumoniae carbapenemase-producing K. pneumoniae: importance of combination therapy.产碳青霉烯酶肺炎克雷伯菌血流感染患者的死亡率预测因素:联合治疗的重要性。
Clin Infect Dis. 2012 Oct;55(7):943-50. doi: 10.1093/cid/cis588. Epub 2012 Jul 2.
3
Risk factors for infection and predictors of mortality among patients with KPC-producing Klebsiella pneumoniae bloodstream infections in the intensive care unit.重症监护病房中产KPC肺炎克雷伯菌血流感染患者的感染危险因素及死亡预测因素。
Scand J Infect Dis. 2014 Sep;46(9):642-8. doi: 10.3109/00365548.2014.923106. Epub 2014 Jul 14.
4
Bloodstream infections due to extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella pneumoniae: risk factors for mortality and treatment outcome, with special emphasis on antimicrobial therapy.产超广谱β-内酰胺酶大肠埃希菌和肺炎克雷伯菌引起的血流感染:死亡率和治疗结果的危险因素,特别强调抗菌治疗。
Antimicrob Agents Chemother. 2004 Dec;48(12):4574-81. doi: 10.1128/AAC.48.12.4574-4581.2004.
5
Bloodstream infections caused by metallo-β-lactamase/Klebsiella pneumoniae carbapenemase-producing K. pneumoniae among intensive care unit patients in Greece: risk factors for infection and impact of type of resistance on outcomes.希腊重症监护病房患者中产金属β-内酰胺酶/肺炎克雷伯菌碳青霉烯酶的肺炎克雷伯菌引起的血流感染:感染的危险因素和耐药类型对结局的影响。
Infect Control Hosp Epidemiol. 2010 Dec;31(12):1250-6. doi: 10.1086/657135. Epub 2010 Oct 25.
6
Infections caused by KPC-producing Klebsiella pneumoniae: differences in therapy and mortality in a multicentre study.由产 KPC 肺炎克雷伯菌引起的感染:一项多中心研究中的治疗和死亡率差异。
J Antimicrob Chemother. 2015 Jul;70(7):2133-43. doi: 10.1093/jac/dkv086. Epub 2015 Apr 21.
7
Predictors of mortality in multidrug-resistant Klebsiella pneumoniae bloodstream infections.多药耐药肺炎克雷伯菌血流感染患者的死亡预测因素。
Expert Rev Anti Infect Ther. 2013 Oct;11(10):1053-63. doi: 10.1586/14787210.2013.836057. Epub 2013 Sep 27.
8
Risk factors and outcomes for bloodstream infections with extended-spectrum beta -lactamase-producing Klebsiella pneumoniae ; Findings of the nosocomial surveillance system in Hungary.产超广谱β-内酰胺酶肺炎克雷伯菌血流感染的危险因素及转归:匈牙利医院监测系统的研究结果
Acta Microbiol Immunol Hung. 2009 Sep;56(3):251-62. doi: 10.1556/AMicr.56.2009.3.5.
9
Molecular epidemiology and risk factors of bloodstream infections caused by extended-spectrum beta-lactamase-producing Klebsiella pneumoniae A case-control study.产超广谱β-内酰胺酶肺炎克雷伯菌所致血流感染的分子流行病学及危险因素:一项病例对照研究
Int J Infect Dis. 2008 Nov;12(6):653-9. doi: 10.1016/j.ijid.2008.03.008. Epub 2008 Jun 3.
10
Evaluation of risk factors for the acquisition of bloodstream infections with extended-spectrum beta-lactamase-producing Escherichia coli and Klebsiella species in the intensive care unit; antibiotic management and clinical outcome.重症监护病房中产超广谱β-内酰胺酶大肠埃希菌和克雷伯菌属血流感染危险因素的评估;抗生素管理及临床结局
J Hosp Infect. 2008 Feb;68(2):108-15. doi: 10.1016/j.jhin.2007.10.011. Epub 2007 Dec 11.

引用本文的文献

1
Ceftazidime-Avibactam Plus Aztreonam for the Treatment of Blood Stream Infection Caused by Resistant to All Beta-Lactame/Beta-Lactamase Inhibitor Combinations.头孢他啶-阿维巴坦联合氨曲南治疗对所有β-内酰胺类/β-内酰胺酶抑制剂组合耐药的血流感染
Antibiotics (Basel). 2025 Aug 7;14(8):806. doi: 10.3390/antibiotics14080806.
2
Phage Host Range Expansion Through Directed Evolution on Highly Phage-Resistant Strains of .通过在高度抗噬菌体菌株上进行定向进化实现噬菌体宿主范围扩展 。 (原文句子不完整,此处补充完整句子结构以便理解翻译内容)
Int J Mol Sci. 2025 Aug 6;26(15):7597. doi: 10.3390/ijms26157597.
3
Evaluation of Infections Caused by Carbapenem-Resistant , , and in an Intensive Care Unit: A Retrospective Study.
重症监护病房中耐碳青霉烯类[细菌名称缺失]和[细菌名称缺失]引起的感染评估:一项回顾性研究
Antibiotics (Basel). 2025 Jul 12;14(7):700. doi: 10.3390/antibiotics14070700.
4
Efficacy of cefoperazone-sulbactam as a component of combination therapy for carbapenem-resistant Acinetobacter baumannii bloodstream infection in intensive care units: a multicenter retrospective propensity score-matched study.头孢哌酮-舒巴坦作为重症监护病房耐碳青霉烯鲍曼不动杆菌血流感染联合治疗方案组成部分的疗效:一项多中心回顾性倾向评分匹配研究
BMC Infect Dis. 2025 Jul 1;25(1):872. doi: 10.1186/s12879-025-11205-w.
5
Unveiling the research advances of sepsis: pathogenesis, precise intervention and clinical perspective.揭示脓毒症的研究进展:发病机制、精准干预及临床展望
Int J Surg. 2025 Jun 23;111(9):6260-89. doi: 10.1097/JS9.0000000000002668.
6
In vitro synergistic effect and mutant prevention concentration of eravacycline alone or in combination with various antibiotics against OXA-48 producing enterobacterales.依拉环素单独或与多种抗生素联合对产OXA-48肠杆菌科细菌的体外协同作用及突变预防浓度
J Antibiot (Tokyo). 2025 May;78(6):370-379. doi: 10.1038/s41429-025-00823-w. Epub 2025 May 7.
7
Investigating Gram-negative bacilli isolates' sensitivity to ceftazidime/avibactam.研究革兰氏阴性杆菌分离株对头孢他啶/阿维巴坦的敏感性。
J Family Med Prim Care. 2025 Jan;14(1):311-316. doi: 10.4103/jfmpc.jfmpc_1272_24. Epub 2025 Jan 13.
8
Carbapenemase Mechanism Testing to Support Treatment, Infection Control, and Public Health: The Role of the Clinical Laboratory.用于支持治疗、感染控制和公共卫生的碳青霉烯酶机制检测:临床实验室的作用
Clin Lab Med. 2025 Mar;45(1):51-61. doi: 10.1016/j.cll.2024.10.006. Epub 2024 Nov 16.
9
Developing and validating a machine learning model to predict multidrug-resistant -related septic shock.开发并验证一个用于预测多重耐药相关感染性休克的机器学习模型。
Front Immunol. 2025 Jan 10;15:1539465. doi: 10.3389/fimmu.2024.1539465. eCollection 2024.
10
Maximally precise combinations to overcome metallo-β-lactamase-producing .最大限度精确组合以克服产金属-β-内酰胺酶的。
Antimicrob Agents Chemother. 2024 Oct 8;68(10):e0077024. doi: 10.1128/aac.00770-24. Epub 2024 Sep 17.